Core Insights - Pfizer announced positive topline results from the Phase 2 FOURLIGHT-1 study for atirmociclib, showing a statistically significant improvement in progression-free survival (PFS) in patients with HR-positive, HER2-negative metastatic breast cancer [1][2][5] Study Results - The study met its primary endpoint with a hazard ratio of 0.60 (95% CI: (0.440, 0.825)), indicating a 40% reduction in the risk of disease progression or death [1][5] - PFS results were consistent across all prespecified subgroups, with over 90% of patients starting treatment within three months of their last CDK4/6 inhibitor [2][5] - Overall survival (OS) data was not mature at the time of analysis, with approximately 20% of participants having an event [2] Safety Profile - Atirmociclib demonstrated a manageable safety profile, with only 6.4% of patients discontinuing due to treatment-emergent adverse events [3][5] - No new safety signals were identified, and the safety profile was consistent with prior studies [3] Development Strategy - The findings support Pfizer's strategy to advance atirmociclib in first-line and early-stage disease, where it may provide greater benefits [4][5] - A Phase 3 registrational study for atirmociclib in the first-line metastatic setting is ongoing, with results from a Phase 2 neoadjuvant study to be shared at a future medical meeting [4]